No prior radiotherapy or chemotherapy, with the exception of dexamethasone, which is allowed
Diagnosis of immunodeficiency or treatment with systemic immunosuppressive therapy within  days prior to the first dose of trial treatment, other than dexamethasone for the underlying disease under investigation, as noted in the inclusion criteria;
Stable dose of dexamethasone  mg or less for at least  days prior to initiation of treatment
Dexamethasone:  days
Stable dose of dexamethasone  mg or less for  days prior to initiation of treatment
Stable dose of dexamethasone  mg or less for  days prior to initiation of treatment
Stable dose of dexamethasone  mg or less for at least  days prior to initiation of treatment
Stable dose of dexamethasone  mg or less for at least  days prior to initiation of treatment
Ongoing treatment with immunosuppressive drugs or dexamethasone >  mg
Daily dexamethasone >  mg at the time of registration
Dexamethasone dose =<  mg daily
If applicable, stable dose of dexamethasone  mg or less for  days prior to initiation of treatment
Use of systemic glucocorticoid (eg, prednisone, dexamethasone) within  days prior to the start of study medication.
Time interval from last systemic chemotherapy (not including low dose dexamethasone) more than  weeks prior to initiation of ABC; patients receiving high dose dexamethasone defined as  mg dexamethasone a day for  days will need  weeks washout prior to initiation of ABC
The subject requires dexamethasone =<  mg daily on a stable dose
No dexamethasone (or other corticosteroid bioequivalent) within one week of vaccination initiation
Patients who are receiving dexamethasone must be on a stable dose for at least  week prior to study entry
Be willing to use dexamethasone mouthwash as directed
Noncompliant with oral medication and/or dexamethasone mouth wash
Any anti-myeloma drug treatment within  days before randomization, including dexamethasone.
Dexamethasone dose less than or equal to  mg daily at time of study enrollment
Glucocorticoid therapy within the  days prior to randomization that exceeds a cumulative dose of  mg of dexamethasone or  mg prednisone
Stable dose of glucocorticoids pre-therapy; if patients are receiving dexamethasone, the dose of dexamethasone should not increase during the  hours prior to initiation of therapy
If patient is on dexamethasone, must be on stable or decreasing dose of dexamethasone for >=  days; if patient is on different glucocorticoid e.g., prednisone, must be converted to dexamethasone prior to enrollment
Prior treatment for myeloma except for one cycle of dexamethasone
Use of systemic glucocorticoid (eg, prednisone, dexamethasone) within  days prior to the start of study medication
Participants in the combination therapy arms must be eligible to receive pomalidomide/dexamethasone, bortezomib/dexamethasone or lenalidomide/dexamethasone or other approved agents per current prescribing information for MM.
Patients with central nervous system (CNS) tumors who are receiving dexamethasone must have been on a stable or decreasing dose of dexamethasone for the  days prior to enrollment
Patients for whom dexamethasone is contraindicated.
Glucocorticoid therapy within  days prior to randomization that equals or exceeds a cumulative dose of  mg of dexamethasone
Patients receiving corticosteroids aside from dexamethasone treatment directed at leukemia
Resistance to high-dose dexamethasone used in the last line of therapy
Use of dexamethasone for cancer related fatigue
Off dexamethasone treatment for ? weeks before the first dose of study drug.
No ongoing requirement for dexamethasone or anti-epileptic drugs.
